Harmony Biosciences HoldingsHRMY -1.15%92 EV-to-FCF is 4.69 as of Jul. 01, 2026, which is 35% below its 10-year median of 7.24. GuruFocus rates HRMY with a GF Score™ of 92/100 and a GF Value™ of $46.51 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 331 Biotechnology companies, Harmony Biosciences Holdings ranks better than 66.77% on this metric.
The historical rank and industry rank for Harmony Biosciences Holdings's EV-to-FCF or its related term are showing as below:
HRMY'
s EV-to-FCF Range Over the Past 10 Years
Min: -1752.23 Med: 7.24 Max: 41.56
Current: 4.69
During the past 8 years, the highest EV-to-FCF of Harmony Biosciences Holdings was 41.56. The lowest was -1752.23. And the median was 7.24.
HRMY's EV-to-FCF is ranked better than 66.77% of 331
companies
in the Biotechnology industry
Industry Median: 15.9
vs HRMY: 4.69
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Harmony Biosciences Holdings's PE Ratio (TTM) for today is calculated as:
Harmony Biosciences Holdings's share price for today is $36.00.
Harmony Biosciences Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.480.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Harmony Biosciences Holdings EV-to-FCF Related Terms
Harmony Biosciences Holdings EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Harmony Biosciences Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harmony Biosciences Holdings EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Harmony Biosciences Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Harmony Biosciences Holdings's EV-to-FCF falls into.
Harmony Biosciences Holdings's current Enterprise Value is $1,602.0 Mil.
Harmony Biosciences Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $341.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harmony Biosciences Holdings (HRMY) has a EV-to-FCF of 4.69 as of Jul. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Harmony Biosciences Holdings and its competitors. This is 35% below median its historical median of 7.24. According to the industry distribution chart, Harmony Biosciences Holdings ranks #110 out of 331 companies in the Biotechnology industry, placing it in the top 33.2%.
Is Harmony Biosciences Holdings' EV-to-FCF too high?
Harmony Biosciences Holdings' current EV-to-FCF of 4.69 is 35% below median its 10-year median of 7.24. The Biotechnology industry median EV-to-FCF is 15.90. Harmony Biosciences Holdings' value of 4.69 is 70.5% below this industry median. Based on the distribution chart, Harmony Biosciences Holdings ranks #110 out of 331 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Harmony Biosciences Holdings has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Harmony Biosciences Holdings' EV-to-FCF compare to KARD and ADMA?
According to the Biotechnology industry distribution chart, Harmony Biosciences Holdings ranks #110 out of 331 companies for EV-to-FCF. This puts Harmony Biosciences Holdings in the upper half of its industry. The industry median EV-to-FCF is 15.90. Harmony Biosciences Holdings' value of 4.69 is 70.5% below this benchmark. While the company's 10-year median is 7.24 vs. the industry median of 15.90, Harmony Biosciences Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.90, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Harmony Biosciences Holdings's current EV-to-FCF of 4.69 is 70.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Harmony Biosciences Holdings and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harmony Biosciences Holdings's current EV-to-FCF is 4.69, which is 35% below median its own 10-year median of 7.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harmony Biosciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Harmony Biosciences Holdings (HRMY) is currently considered Modestly Undervalued. The stock's GF Value™ is $46.51, compared to a current price of $36.00 — trading 22.6% below its estimated fair value. The current EV-to-FCF is 4.69, which is 35% below median its 10-year median of 7.24 and 70.5% below the Biotechnology industry median of 15.90. Harmony Biosciences Holdings' overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Harmony Biosciences Holdings (HRMY), the current EV-to-FCF is 4.69 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harmony Biosciences Holdings (HRMY) Overvalued in 2026?
Based on GuruFocus' analysis, Harmony Biosciences Holdings stock appears to be undervalued.
The current stock price of $36.00 is trading 22.6% below its estimated GF Value™ of $46.51.
GuruFocus considers Harmony Biosciences Holdings to be Modestly Undervalued.
Key valuation signals for HRMY:
EV-to-FCF: 4.69 (35% below median its 10-year median of 7.24)
GF Value™: $46.51 vs. price of $36.00 (22.6% below fair value)
Industry Position: 70.5% below the Biotechnology median (#110 of 331)
No single metric tells the full story. See the HRMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
92GF Score
Get the complete analysis for HRMY
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HRMY has been successfully added to your 
